Potential of Liquid Biopsy in Papillary Thyroid Carcinoma in Context of miRNA, BRAF and p53 Mutation

Author(s): Ewelina Perdas*, Robert Stawski, Dariusz Nowak, Maria Zubrzycka.

Journal Name: Current Drug Targets

Volume 19 , Issue 14 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Liquid biopsy is a minimally invasive detection method for molecular biomarkers such as miRNA and cell free DNA in body fluids. Deregulations of miRNA are involved in papillary thyroid carcinoma (PTC), one the most common endocrine malignancy. The most widespread common mutations detected in papillary thyroid cancers are BRAF mutations. Many studies indicate that the BRAF mutation is related to deregulation of miRNA. p53 has an important role in cell cycle control, DNA repair and apoptosis. Moreover, the p53 can regulate the expression of miRNAs and thus participate in thyroid oncogenesis.

Objective: In this review, we briefly summarize the present state of knowledge about miRNA, BRAF and p53 mutation in the development of PTC and the possibility of using detecting BRAF mutation and miRNA expression in liquid biopsy.

Results: The use of the plasma miRNA expression profile in combination with the BRAF mutation analysis in cf-DNA may be a valuable tool in management of PTC.

Conclusion: Numerous molecular variation characterize recent diagnostic and prognostic markers and therapeutic targets for this type of cancer, which offer unique chances for further research and clinical development of innovative treatment strategies for thyroid cancer.

Keywords: miRNA, papillary thyroid cancer, liquid biopsy, BRAF mutation, MAPK pathway, tumor protein p53, cf-DNA.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 14
Year: 2018
Page: [1721 - 1729]
Pages: 9
DOI: 10.2174/1389450119666180226124349
Price: $58

Article Metrics

PDF: 22
HTML: 5